- Home
- LEGH vs PCRX Comparison
LEGH vs PCRX Comparison
Compare LEGH & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- PCRX
- Stock Information
- Founded
- LEGH 2005
- PCRX 2006
- Country
- LEGH United States
- PCRX United States
- Employees
- LEGH N/A
- PCRX N/A
- Industry
- LEGH Homebuilding
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- PCRX Health Care
- Exchange
- LEGH Nasdaq
- PCRX Nasdaq
- Market Cap
- LEGH 588.8M
- PCRX 1.2B
- IPO Year
- LEGH 2018
- PCRX 2011
- Fundamental
- Price
- LEGH $23.43
- PCRX $23.25
- Analyst Decision
- LEGH Strong Buy
- PCRX Buy
- Analyst Count
- LEGH 2
- PCRX 9
- Target Price
- LEGH $29.00
- PCRX $29.89
- AVG Volume (30 Days)
- LEGH 105.1K
- PCRX 546.0K
- Earning Date
- LEGH 08-07-2025
- PCRX 07-29-2025
- Dividend Yield
- LEGH N/A
- PCRX N/A
- EPS Growth
- LEGH 8.04
- PCRX N/A
- EPS
- LEGH 2.29
- PCRX N/A
- Revenue
- LEGH $176,618,000.00
- PCRX $702,772,000.00
- Revenue This Year
- LEGH N/A
- PCRX $7.54
- Revenue Next Year
- LEGH $8.23
- PCRX $10.78
- P/E Ratio
- LEGH $10.36
- PCRX N/A
- Revenue Growth
- LEGH N/A
- PCRX 3.08
- 52 Week Low
- LEGH $21.58
- PCRX $11.16
- 52 Week High
- LEGH $29.31
- PCRX $29.33
- Technical
- Relative Strength Index (RSI)
- LEGH 59.31
- PCRX 35.57
- Support Level
- LEGH $21.91
- PCRX $23.24
- Resistance Level
- LEGH $22.99
- PCRX $25.16
- Average True Range (ATR)
- LEGH 0.65
- PCRX 0.77
- MACD
- LEGH 0.19
- PCRX -0.12
- Stochastic Oscillator
- LEGH 73.41
- PCRX 4.74
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.